Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity

References

• Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol.. 2005;23(28):7161–7167.
   PubMed Web of Science ®Google Scholar
• Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood. 2000;96(5):1709–1715.
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238–249.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97(5):1211–1218.
   PubMed Web of Science ®Google Scholar
• Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00–01. J Clin Oncol. 2013;31(9):1202–1210.
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24–31.
   PubMed Web of Science ®Google Scholar
• Appel IM, Azemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: Results from a single agent window study. Leukemia. 2008;22(9):1665–1679.
   PubMed Web of Science ®Google Scholar
• Rytting M. PEG-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010;10(5):833–839.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99(6):1986–1994.
   PubMed Web of Science ®Google Scholar
• Lanvers-Kaminsky C, Rüffer A, Würthwein G, et al. Therapeutic drug monitoring of asparaginase activity-method comparison of MAAT and AHA test used in the International AIEOP-BFM ALL 2009 trial. Ther Drug Monit. 2017;40:1–102.
   Web of Science ®Google Scholar
• Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01190930
   Google Scholar
• International Collaborative Treatment Protocol for Children and Adolescents with Acute Lymphoblastic Leukemia. Retrieved from https://clinicaltrials.gov/ct2/show/NCT01117441
   Google Scholar
• Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014;123(13):2026–2033.
   PubMed Web of Science ®Google Scholar
• Kloos RQH, Uyl-de Groot CA, van Litsenburg RRL, Kaspers GJL, Pieters R, van der Sluis IM. A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64:e26651.
   Web of Science ®Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly dignosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomized, open-label phase 3 study. Lancet Oncol. 2015;16(16):1677–1690.
   PubMed Web of Science ®Google Scholar
• Nesbit M, Chard R, Evans A, Hammond GD. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol/Oncol. 1979;1:9–13.
   PubMedGoogle Scholar
• Petersen WC, Jr, Clark D, Senn SL, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31(4):311–317.
   PubMed Web of Science ®Google Scholar
• Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer. 2012;59(3):436–439.
   PubMed Web of Science ®Google Scholar
• August KJ, Miller WP, Dalton A, Shinnick S. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration. J Pediatr Hematol Oncol. 2013;35:283–286.
   PubMed Web of Science ®Google Scholar
• Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109(3):896–904.
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;26(4):217–226.
   PubMed Web of Science ®Google Scholar
• Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse. A Children’s Oncology Group Study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610–616.
   PubMed Web of Science ®Google Scholar
• Tong WH, Pieters R, de Groot-Kruseman HA, et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. Haematologica 2014;99(11):1716–1721.
   PubMed Web of Science ®Google Scholar